Skip to content
Recall Observatory FDA recall evidence

Device product

BD BBL Sensi Disc Levofloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231705 and 231706¿

Z-1032-2024

January 08, 2024

Class II

Product summary

Firm
Becton Dickinson & Co.
Event
Event 93789
Status
Ongoing
Classification
Class II
Quantity
2,363,168 total units
Official record key
device-enforcement:Z-1032-2024

Official wording

Reason: There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

Code information: Catalog No. 231705 UDI-DI 00382902317050 Lots 1334510 2004644 2091272 2277179 3030830 3094117 3248344; Catalog No. 231706¿ UDI-DI 30382902317068 Lots 2277179 3030830 3094117 3184118 3248344 1334510 2004644 2091272 2213599

Distribution pattern: Domestic distribution nationwide. International distribution worldwide.

Derived failure modes

  • Unknown

    reason.no_named_rule · v1.0.0

    There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.